| Prev Close | 1.55 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 1.42 / 4.84 |
| Avg Volume | 260.40K |
| Exchange | AMEX |
| Shares Outstanding | 31.74M |
| Market Cap | 50.16M |
| EPS | -0.90 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Encouraging Progression Free Survival and Evidence of Tumor Shrinkage Observed in Patients with Advanced Bladder Cancer Who Had Failed on Multiple Prior Treatments Including Immunotherapy and Gemcitabine
Patent Protection for RX-5902 (Supinoxin™) Extended until 2036 for Multiple Cancers including Triple Negative Breast Cancer
RX-3117 Monotherapy Increased Progression Free Survival and Showed Evidence of Tumor Shrinkage in Patients with Advanced Bladder Cancer Resistant to Gemcitabine who had failed on Multiple Prior Treatments
Patent Protection Extended until 2034
Patent Protection for RX-3117 Extended until 2036
